Saglik Bilimleri Universitesi

sbu.edu.tr

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

532

Active

156

Phase 3

1

Total enrollment

51,567

Pipeline matrix

Showing 14 of 14 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Remifentanil3
control group2
Bupivacaine2
Normal Saline2
Dexmedetomidine2
Hyaluronic Acid (0.8%) - Applied over CTG before flap closure (Test group only).1
Experimental Group1
Aflibercept biosimilar1
N2O1
Fentanyl1
Gene Expression Analysis1
Midazolam1
Nicardipine1
Salbutamol1

Next readouts

  • 2024-09-30
  • 2025-06-01
  • 2025-06-15
  • 2026-01-01
  • 2026-03-01
  • 2026-05-14
  • 2026-06-20
  • 2026-07-01
  • 2026-08-01

Top conditions

  • Anxiety26
  • Pain25
  • Quality of Life13
  • Breast Cancer11
  • Periodontitis8
  • Nursing Caries8
  • Stress7
  • Telerehabilitation7

Frequently asked questions about Saglik Bilimleri Universitesi

How many clinical trials does Saglik Bilimleri Universitesi have on ClinicalTrials.gov?
Saglik Bilimleri Universitesi is listed as the lead sponsor on 532 clinical trials in ClinicalTrials.gov, 156 of which are currently active (recruiting, enrolling, or ongoing).
How many of Saglik Bilimleri Universitesi's trials are in Phase 3?
1 of Saglik Bilimleri Universitesi's trials are in Phase 3, spread across 14 active drug programs.
What therapeutic areas does Saglik Bilimleri Universitesi focus on?
Saglik Bilimleri Universitesi's most-studied conditions on ClinicalTrials.gov are Anxiety, Pain, Quality of Life, Breast Cancer, Periodontitis.
When are Saglik Bilimleri Universitesi's next clinical trial readouts?
Saglik Bilimleri Universitesi has 9 upcoming primary-completion readouts tracked here; the soonest is “Efficacy of Remifentanil in Preventing Emergence Agitation”, expected around 2024-09-30.